Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
Shannan, CN
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.18% | -1.96% | -7.13% | +10.55% | -13.79% | +0.49% | +13.44% | +95.19% | +124.51% | +233.14% | +632.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+16.8% ★ Q1'26: +75.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-34.3% Q1'26: +1,150.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+7.2% ★ Q1'26: +17.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+4.0% ★ Q1'26: +35.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3.4% ★ Q1'26: +40.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -3.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.44× Q1'26: 1.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.21B
est: 1.45B (-16.6%)
|
1.44B
est: 1.46B (-1.9%)
|
1.86B
est: 1.60B (+15.7%)
|
3.43B
est: 2.69B (+27.5%)
|
3.94B
est: 3.94B (0.0%)
|
3.33B
est: 3.34B (-0.2%)
|
2.77B
est: 2.91B (-4.6%)
|
3.02B
est: 2.97B (+1.4%)
|
3.36B
est: 3.36B (+0.0%)
|
3.72B
est: 3.82B (-2.5%)
|
4.35B
est: 4.49B (-3.2%)
|
6.06B
5.52B – 6.60B
+35.0% YoY
|
6.58B
6.25B – 6.90B
+8.4% YoY
|
7.83B
7.30B – 8.36B
+19.1% YoY
|
11.26B
10.50B – 12.03B
+43.8% YoY
|
| EBITDA |
390.98M
est: 165.08M (+136.8%)
|
322.41M
est: 166.11M (+94.1%)
|
172.16M
est: 182.11M (-5.5%)
|
235.33M
est: 305.08M (-22.9%)
|
410.94M
est: 447.11M (-8.1%)
|
332.93M
est: 378.87M (-12.1%)
|
183.93M
est: 329.97M (-44.3%)
|
317.33M
est: 337.55M (-6.0%)
|
544.25M
est: 380.92M (+42.9%)
|
498.35M
est: 437.49M (+13.9%)
|
459.12M
est: 514.89M (-10.8%)
|
695.28M
633.25M – 757.30M
+35.0% YoY
|
753.94M
716.59M – 791.30M
+8.4% YoY
|
897.93M
836.73M – 959.14M
+19.1% YoY
|
1.29B
1.20B – 1.38B
+43.8% YoY
|
| EBIT |
338.17M
est: 86.75M (+289.8%)
|
260.92M
est: 87.29M (+198.9%)
|
109.01M
est: 95.70M (+13.9%)
|
163.17M
est: 160.32M (+1.8%)
|
323.01M
est: 234.96M (+37.5%)
|
228.35M
est: 199.11M (+14.7%)
|
37.60M
est: 173.40M (-78.3%)
|
141.57M
est: 177.39M (-20.2%)
|
331.58M
est: 200.18M (+65.6%)
|
262.03M
est: 206.17M (+27.1%)
|
175.74M
est: 242.64M (-27.6%)
|
327.65M
298.42M – 356.88M
+35.0% YoY
|
355.30M
337.69M – 372.90M
+8.4% YoY
|
423.15M
394.31M – 451.99M
+19.1% YoY
|
608.61M
567.13M – 650.09M
+43.8% YoY
|
| Net Income |
372.16M
est: 649.55M (-42.7%)
|
442.78M
est: 414.37M (+6.9%)
|
237.55M
est: 515.16M (-53.9%)
|
333.23M
est: 335.98M (-0.8%)
|
493.89M
est: 509.56M (-3.1%)
|
636.62M
est: 649.55M (-2.0%)
|
345.06M
est: 346.05M (-0.3%)
|
277.07M
est: 358.37M (-22.7%)
|
295.11M
est: 291.18M (+1.4%)
|
395.46M
est: 418.10M (-5.4%)
|
259.58M
est: 436.77M (-40.6%)
|
895.93M
559.16M – 1.23B
+105.1% YoY
|
702.75M
640.48M – 765.02M
-21.6% YoY
|
926.73M
844.62M – 1.01B
+31.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
451.60M
est: 687.58M (-34.3%)
|
765.78M
est: 691.83M (+10.7%)
|
940.83M
est: 758.51M (+24.0%)
|
1.51B
est: 1.27B (+19.0%)
|
1.97B
est: 1.86B (+5.7%)
|
1.58B
est: 1.58B (+0.0%)
|
1.32B
est: 1.37B (-3.6%)
|
1.46B
est: 1.41B (+4.1%)
|
1.52B
est: 1.59B (-4.1%)
|
1.76B
est: 1.80B (-2.1%)
|
2.04B
est: 2.12B (-3.6%)
|
2.86B
2.61B – 3.12B
+35.0% YoY
|
3.10B
2.95B – 3.26B
+8.4% YoY
|
3.70B
3.45B – 3.95B
+19.1% YoY
|
5.32B
4.96B – 5.68B
+43.8% YoY
|
| EPS |
0.35
est: 0.58 (-39.7%)
|
0.41
est: 0.37 (+10.8%)
|
0.22
est: 0.46 (-52.2%)
|
0.31
est: 0.30 (+3.3%)
|
0.46
est: 0.46 (+1.1%)
|
0.60
est: 0.58 (+3.4%)
|
0.32
est: 0.31 (+3.6%)
|
0.26
est: 0.32 (-18.8%)
|
0.27
est: 0.26 (+3.8%)
|
0.35
est: 0.37 (-6.2%)
|
0.23
est: 0.39 (-41.0%)
|
0.80
0.50 – 1.10
+105.1% YoY
|
0.63
0.57 – 0.68
-21.6% YoY
|
0.83
0.75 – 0.90
+31.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Han Bing Liu | Human Resources Manager | — | female |
| Meng Wang | Deputy GM & Board Secretary | — | male |
| Pangke Yan | GM & Director | — | male |
| Peng Duan | Chief Financial Officer | — | female |
| Xiu Lian Fan | MD, GM & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002653.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
